Breaking News, Financial News

Biogen Idec

Tysabri sales fuel growth

Biogen Idec 1Q10

1Q Revenues: $1.1 billion (+7%)

1Q Earnings: $220 million (-11%)

Comments: Tysabri sales rose 32% to $219 million in the quarter, while Avonex sales were up 7% to $593 million. Rituxan revenues dropped 9% to $255 million. BI wrote down $14 million from its investment in AVEO Pharmaceuticals, and another $13 million in expanded Medicaid rebates.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters